Page 1,859«..1020..1,8581,8591,8601,861..1,8701,880..»

Bowman doctor brings stem cell therapy to North Dakota …

Posted: February 15, 2015 at 5:58 am

Image

Dr. Forrest Lanchbury, a specialist in anti-aging and regenerative medicine and medical director at Bowmans Southwest Healthcare Services, looks on as registered nurse Chrissy Blankenbaker works on a plasma-rich platelet procedure on Jan. 29 at the facility. Lanchbury and his team became the first to offer stem cell and PRP therapy in North Dakota in November. (Nadya Faulx / Forum News Service)

BOWMAN, N.D. -- Southwest North Dakota is a place known more for its oil industry than its health care, but one doctor is putting the region on the map with a new cutting-edge medical procedure that's attracting patients from across the state.

Dr. Forrest Lanchbury and a team of nurses now provide stem cell therapy to patients at Bowman's Southwest Healthcare Services, making it the only facility in North Dakota to offer the procedure, in which a patient's own stem cells are injected to a specific site in order to encourage healing.

Lanchbury, the facility's medical director, performed the first stem cell therapy in November, and has performed five total since the procedure became available.

"Everybody was really interested in it," he said, "and impressed with the potential to help patients."

Stem cell therapy is used to treat a multitude of ailments, from heart disease to neurological disorders, but Lanchbury said most of the patients who have undergone the procedure in Bowman do so to treat osteoarthritis and other joint diseases.

Stem cells multiply rapidly and can turn into other types of tissues and cells, depending on what needs to be healed, Lanchbury explained, meaning they have "the potential to heal any type of damaged tissue."

"Most healing takes place in any place in our body is done by stem cells," he said. "A cut, any injury to a tendon or ligament, or arthritis -- stem cells are involved within the body in healing that."

The process is deceptively simple: It involves harvesting an adult's own stem cells via liposuction (stem cells are also found in bone marrow, but are more plentiful in fat), mixing them with platelet-rich plasma and injecting the solution into the tendon or joint being treated.

View post:
Bowman doctor brings stem cell therapy to North Dakota ...

Posted in North Dakota Stem Cells | Comments Off on Bowman doctor brings stem cell therapy to North Dakota …

Stem Cell Advances Bring Hope to Fibromyalgia Treatments – Video

Posted: February 14, 2015 at 8:40 pm


Stem Cell Advances Bring Hope to Fibromyalgia Treatments
With new advances in stem cell research, patients suffering from Fibromyalgia and other ailments may soon be able to see drastic improvements in their conditions. These advances in new Fibromyalgia ...

By: Mississippi Stem Cell Treatment Center

Follow this link:
Stem Cell Advances Bring Hope to Fibromyalgia Treatments - Video

Posted in Stem Cell Research | Comments Off on Stem Cell Advances Bring Hope to Fibromyalgia Treatments – Video

Stem Cell Therapies

Posted: February 14, 2015 at 8:58 am

A new Phase I trial involving the use of stem cells in Multiple Sclerosis (MS) patients is underway in a study by the Cleveland Clinic, Case Western Reserve University, and University Hospitals Seidman Cancer Center. Multiple Sclerosis is an autoimmune disease, wherein the immune system attacks the central nervous system (CNS), both the brain and spinal cord.

So far, 2 patients have undergone the complete process, with another patient expecting to start the process soon. In all, 24 patients with relapsing or progressively worsening MS will be in the trial over the next 2 to 3 years. The protocol calls for harvesting of their own stem cells from bone marrow at the University Hospital, cultivating those cells at a Case Western laboratory, and then returning the stem cells to the patient intravenously at the Cleveland Clinic.

The primary focus of this study is to determine both the feasibility and the safety of such a treatment process. In the process, the researchers will also be looking for any evidence of improvement in the patients, although the trial is not set up to actually gauge either subjective or objective endpoints. This is a conservative study that will only look at safety parameters. If the trial goes well, further Phase II trials would likely follow, with actual treatment endpoints as the focus.

The first patient treated in the trial, Bill White, was first diagnosed with MS about 6 years ago. His first symptoms were fatigue and balance problems. After a while, exercise and even walking became problematic for him, and he eventually had to stop working. The reason for these issues is that in MS, the immune system abnormally attacks the CNS, leading to damage in the protective myelin sheaths, followed by irreversible damage to the axons and even neuronal death. The damage builds up and can progressively worsen over time, or can occur in a relapse and remission format. The process leads to noticeable changes on MRI and the diagnosis can be confirmed by looking at the spinal fluid. Mr. White had the characteristic changes on a scan of his brain in 2007. He has also since undergone treatment with 2 different drugs without seeing much benefit, if any, while subjecting him to a variety of side-effects.

After enrolling in this trial, his stem cells were harvested in March. The stem cells were cultured in the lab for months, and they were eventually injected into his bloodstream in June. Mr. White saw changes very quickly. He stated that "I used to have to use my left arm to lift my left leg up. Now I can lift it up on my own", meaning without the assistance of his arm. And although he still tires when walking, he does so less quickly now. In addition, his vision has improved from 20/50 to 20/20. Objectively, a recent MRI showed no new lesions in his brain. The proposed mechanism of action for the stem cells is in modulating the immune system, causing a decrease in the immune attack on the CNS. Also, the stem cells may be promoting the healing and regrowth of damaged tissues.

Other Phase I trials looking at stem cells and MS will soon be underway in Spain, China, and Iran. These are exciting times for sure, and the idea that a patient's own stem cells could help with the treatment of MS is truly amazing!

Read the original post:
Stem Cell Therapies

Posted in Colorado Stem Cells | Comments Off on Stem Cell Therapies

Observing stem cells maturing into blood cells in living mouse

Posted: February 13, 2015 at 5:48 pm

In the bone marrow, blood stem cells give rise to a large variety of mature blood cells via progenitor cells at various stages of maturation. Scientists from the German Cancer Research Center (DKFZ) have developed a way to equip mouse blood stem cells with a fluorescent marker that can be switched on from the outside. Using this tool, they were able to observe, for the first time, how stem cells mature into blood cells under normal conditions in a living organism. With these data, they developed a mathematical model of the dynamics of hematopoiesis. The researchers have now reported in the journal Nature that the normal process of blood formation differs from what scientists had previously assumed when using data from stem cell transplantations.

Since ancient times, humankind has been aware of how important blood is to life. Naturalists speculated for thousands of years on the source of the body's blood supply. For several centuries, the liver was believed to be the site where blood forms. In 1868, however, the German pathologist Ernst Neumann discovered immature precursor cells in bone marrow, which turned out to be the actual site of blood cell formation, also known as hematopoiesis. Blood formation was the first process for which scientists formulated and proved the theory that stem cells are the common origin that gives rise to various types of mature cells.

"However, a problem with almost all research on hematopoiesis in past decades is that it has been restricted to experiments in culture or using transplantation into mice," says Professor Hans-Reimer Rodewald from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). "We have now developed the first model where we can observe the development of a stem cell into a mature blood cell in a living organism."

Dr. Katrin Busch from Rodewald's team developed genetically modified mice by introducing a protein into their blood stem cells that sends out a yellow fluorescent signal. This fluorescent marker can be turned on at any time by administering a specific reagent to the animal. Correspondingly, all daughter cells that arise from a cell containing the marker also send out a light signal.

When Busch turned on the marker in adult animals, it became visible that at least one third (approximately 5000 cells) of a mouse's hematopoietic stem cells produce differentiated progenitor cells. "This was the first surprise," says Busch. "Until now, scientists had believed that in the normal state, very few stem cells -- only about ten -- are actively involved in blood formation."

However, it takes a very long time for the fluorescent marker to spread evenly into peripheral blood cells, an amount of time that even exceeds the lifespan of a mouse. Systems biologist Prof. Thomas Hfer and colleagues (also of the DKFZ) performed mathematical analysis of these experimental data to provide additional insight into blood stem cell dynamics. Their analysis showed that, surprisingly, under normal conditions, the replenishment of blood cells is not accomplished by the stem cells themselves. Instead, they are actually supplied by first progenitor cells that develop during the following differentiation step. These cells are able to regenerate themselves for a long time -- though not quite as long as stem cells do. To make sure that the population of this cell type never runs out, blood stem cells must occasionally produce a couple of new first progenitors.

During embryonic development of mice, however, the situation is different: To build up the system, all mature blood and immune cells develop much more rapidly and almost completely from stem cells.

The investigators were also able to accelerate this process in adult animals by artificially depleting their white blood cells. Under these conditions, blood stem cells increase the formation of first progenitor cells, which then immediately start supplying new, mature blood cells. In this process, several hundred times more cells of the so-called myeloid lineage (thrombocytes, erythrocytes, granulocytes, monocytes) form than long-lived lymphocytes (T cells, B cells, natural killer cells) do.

"When we transplanted our labeled blood stem cells from the bone marrow into other mice, only a few stem cells were active in the recipients, and many stem cells were lost," Rodewald explains. "Our new data therefore show that the findings obtained up until now using transplanted stem cells can surely not be reflective of normal hematopoiesis. On the contrary, transplantation is an exception [to the rule]. This shows how important it is that we actually follow hematopoiesis under normal conditions in a living organism."

The scientists in Rodewald's department, working together with Thomas Hfer, now also plan to use the new model to investigate the impact of pathogenic challenges to blood formation: for example, in cancer, cachexia or infection. This method would also enable them to follow potential aging processes that occur in blood stem cells in detail as they occur naturally in a living organism.

Excerpt from:
Observing stem cells maturing into blood cells in living mouse

Posted in Stem Cells | Comments Off on Observing stem cells maturing into blood cells in living mouse

Stem cells offer promising key to new malaria drugs: US research

Posted: February 13, 2015 at 5:48 pm

NEW YORK (Thomson Reuters Foundation) - Human stem cells engineered to produce renewable sources of mature, liver-like cells can be grown and infected with malaria to test potentially life-saving new drugs, according to researchers at the Massachusetts Institute of Technology.

The advance comes at a time when the parasitic mosquito-borne disease, which kills nearly 600,000 people every year, is showing increased resistance to current treatment, especially in Southeast Asia, according to the World Health Organization.

The liver-like cells, or hepatocytes, in the MIT study were manufactured from stem cells derived from donated skin and blood samples.

The resulting cells provide a potentially replenishable platform for testing drugs that target the early stage of malaria, when parasites may linger and multiply in the liver for weeks before spreading into the bloodstream.

Sangeeta Bhatia, a biomedical engineer and senior author of the MIT report, told the Thomson Reuters Foundation that the breakthrough study not only showed that these liver-like cells could host a malaria infection but also described a way to mature the young cells so that an adult-like metabolism, necessary for drug development, could be established.

The study is published in the Feb. 5 online issue of Stem Cell Reports.

Stem cells retain the genetic makeup of their donors, affording researchers the potential to test drugs against a large variety of genetic types and a variety of diseases.

"This allows us to explore in depth how different diseases affect different people, in this case malaria," Bob Palay, chairman and CEO of Cellular Dynamics International (CDI), told the Thomson Reuters Foundation.

"This allows you to study it in a dish and find new drugs," he added, noting that CDI uses blood samples for its stem cells.

Before this development, researchers tested new drugs using human liver cells from cadavers and cancerous liver cells.

Original post:
Stem cells offer promising key to new malaria drugs: US research

Posted in Stem Cells | Comments Off on Stem cells offer promising key to new malaria drugs: US research

FAQ Part 1: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) – Video

Posted: February 13, 2015 at 5:40 pm


FAQ Part 1: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS)
The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEse...

By: MSSocietyCanada

View original post here:
FAQ Part 1: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) - Video

Posted in Cell Therapy | Comments Off on FAQ Part 1: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) – Video

terapia celular para cinomose – distemper stem cell therapy – Video

Posted: February 13, 2015 at 5:40 pm


terapia celular para cinomose - distemper stem cell therapy
Caso de cinomose tratado com terapia celular - unesp - botucatu Stem cell therapy for distemper in a dog.

By: Jean Joaquim

See original here:
terapia celular para cinomose - distemper stem cell therapy - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on terapia celular para cinomose – distemper stem cell therapy – Video

Stem Cell Therapy for Erectile Dysfunction – Alvarado Hospital – Video

Posted: February 13, 2015 at 5:40 pm


Stem Cell Therapy for Erectile Dysfunction - Alvarado Hospital
The first study in the U.S. to determine if stem cell therapy can treat erectile dysfunction. Alvarado Hospital #39;s Drs. Irwin Goldstein and Barry Handler discuss this FDA-approved study and...

By: AlvaradoHospital

Excerpt from:
Stem Cell Therapy for Erectile Dysfunction - Alvarado Hospital - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Stem Cell Therapy for Erectile Dysfunction – Alvarado Hospital – Video

Grace Centurys Portfolio Project Board Member Asked to Serve on Bahamian Pre-Clearance Stem Cell Ethics Committee

Posted: February 13, 2015 at 5:40 pm

Ras Al Khaimah, UAE (PRWEB) February 12, 2015

Private equity and international research consultancy, Grace Centurys portfolio company, Provia Laboratories, LLC, has announced, just days after the provisional approval of the firms new entrance into the Commonwealth, that Dr. James A. Manganello has been invited to serve on a newly formed pre-clearance team for future entities applying for activity in the Caribbean nation.

The purpose of this team, led by Dr. Desiree Cox, Rhodes Scholar, MD, Ph.D., MPhil, is to provide quality control of the stem cell research and stem cell therapy applications submitted to the Bahamian National Stem Cell Ethics Committee.

"This further demonstrates Provias leadership in this field. Provia has advised pharmaceutical/biotech companies and consulted on multiple initiatives within the National Institutes of Health (NIH) in the field of biobanking for many years now. The team has established itself as a group of thought leaders in the field of bio-banking and stem cell science, Scott Wolf, CEO of Grace Century, commented.

The commonwealth continues to fortify its vision for establishing the nation as a true global force in health care innovations and in the future of the stem cell industry, Wolf added.

I am truly honored to be invited to participate on such an important team, Dr. Manganello said. The Bahamian government, with the help of local businesses, the medical community, and local investors, are trying to attract the best technologies from around the world, and to establish itself as a destination for innovative healthcare. I am excited to do my part to help ensure the highest quality and standards are adhered to.

About Grace Century Grace Century FZ LLC is an International research and private equity consultancy located in Ras Al Khaimah, (north of Dubai) in the United Arab Emirates (UAE). Grace Century specializes in game-changing life science and health related private equity projects.

About Provia Laboratories, LLC Headquartered in Littleton, MA, Provia Laboratories, LLC is a healthcare services company specializing in high-quality bio-banking (the collection, transport, processing and cryogenic storage of biological specimens). Provia Labs offers the Proviasette product range for use in bio-banking environments to improve sample logistics, security and quality. The company manages and promotes its own bio-bank for a dental stem cell banking service, Store-A-Tooth, which gives families the option to store stem cells to protect their childrens future health and take advantage of advances in stem cell therapies. Provia advises industrial, academic and governmental clients on matters related to the preservation of biological specimens for research and clinical use. Provia Labs is a member of ISBER, the International Society for Biological and Environmental Repositories, as well as ESBB, the European, Middle Eastern & African Society for Bio-preservation & Bio-banking. For further information about Provia Labs products and services, call +1 (781) 652-4815 or visit http://www.store-a-tooth.com.

Originally posted here:
Grace Centurys Portfolio Project Board Member Asked to Serve on Bahamian Pre-Clearance Stem Cell Ethics Committee

Posted in Cell Therapy | Comments Off on Grace Centurys Portfolio Project Board Member Asked to Serve on Bahamian Pre-Clearance Stem Cell Ethics Committee

New Jersey Commission Science and Technology Grants – Stem …

Posted: February 13, 2015 at 3:55 pm

Martin Grumet, Ph.D. Professor, Department of Cell Biology and Neuroscience Director, W.M. Keck Center for Collaborative Neuroscience Rutgers Stem Cell Research Center

Modulation of recovery from neural trauma by neural stem cells

Neural stem cells give rise to neurons and glia during development providing most of the cells that form the nervous system but very few stem cells persist in the adult brain. Transplantation of neural stem and progenitor cells into the injured central nervous system is a promising approach to promote repair and recovery after injury. Towards that goal, we are analyzing the development of different kinds of neural cells that can be derived from embryonic stem (ES) cells in the laboratory and testing their behavior after transplantation into the injured nervous system.

Ronald P. Hart, Ph.D. Professor, Department of Cell Biology and Neuroscience W.M. Keck Center for Collaborative Neuroscience Rutgers Stem Cell Research Center

Regulation of microRNA gene expression in differentiating neural stem cells

The key to transforming human stem cells into therapeutic transplants is the faithful control of differentiation the process by which cells acquire specialized functions during embryogenesis in the culture dish. A newly-discovered class of regulatory molecules, known as microRNAs, has been discovered to be required for stem cell differentiation. Our experiments will help to define groups of microRNAs that are regulated during neurogenesis and how they work to control production of neurons or non-neuronal cells in the nervous system. We propose that addition of artificial microRNA molecules will help control differentiation of stem cells prior to transplant, helping to guide the differentiation process towards cell types that are desired and away from products that are unwanted, and enhancing the utility and safety of therapeutic stem cells.

Melitta Schachner, Ph.D. Research Professor II New Jersey Professor of Spinal Cord Research W.M. Keck Center for Collaborative Neuroscience Department of Cell Biology and Neuroscience

Therapeutic use of genetically engineered human ES cells overexpressing the neural cell adhesion molecule L1

My research focuses on recognition molecules found on or near the surface of nerve cells. These molecules tell cells whether they can bind together, an activity important in repairing damaged nervous system tissue. The neural cell adhesion molecule L1 regulates brain development by promoting contacts between nerve cells, thus generating a functional nervous system. Its beneficial influence is important for regeneration after trauma, for example, in spinal cord injury or Huntington's and Parkinson's diseases. When overexpressed in mouse ES cells, L1 enhances survival of imperiled host nerve cells, makes the overexpressing stem cells migrate better in the host tissue, and helps form connections between the transplanted stem cells and the host leading to functional recovery. Important also is its ability to halt tumor formation. We are working toward developing human ES cell lines which overexpress L1, monitor their beneficial potential, and expand their therapeutic potential.

Jay A. Tischfield, Ph.D., FACMG Duncan and Nancy MacMillan Prof of Genetics & Chair (Prof of Pediatrics and Psychiatry, Robert Wood Johnson Medical School, UMDNJ) Rutgers University Cell and DNA Repository

Originally posted here:
New Jersey Commission Science and Technology Grants - Stem ...

Posted in New Jersey Stem Cells | Comments Off on New Jersey Commission Science and Technology Grants – Stem …

Page 1,859«..1020..1,8581,8591,8601,861..1,8701,880..»